Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

The correct approach to purchasing testosterone in the USA requires careful analysis and attention to detail, here are the 3 best brands of testosterone for sale.

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...

CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...